4basebio (4BB) Competitors GBX 967.50 -17.50 (-1.78%) As of 07/2/2025 07:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock 4BB vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, BVXP, and AVCTShould you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry. 4basebio vs. Its Competitors Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Circassia Group Bioventix Avacta Group Silence Therapeutics (LON:SLN) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do institutionals and insiders hold more shares of SLN or 4BB? 2.0% of 4basebio shares are owned by institutional investors. 68.4% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to SLN or 4BB? In the previous week, 4basebio had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for 4basebio and 0 mentions for Silence Therapeutics. 4basebio's average media sentiment score of 0.84 beat Silence Therapeutics' score of 0.00 indicating that 4basebio is being referred to more favorably in the news media. Company Overall Sentiment Silence Therapeutics Neutral 4basebio Positive Do analysts rate SLN or 4BB? 4basebio has a consensus price target of GBX 1,600, suggesting a potential upside of 65.37%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Silence Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.004basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, SLN or 4BB? Silence Therapeutics has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics£11.35M0.00N/A-£48.60N/A4basebio£311K398.51-£9.84M-£0.78-1,240.38 Is SLN or 4BB more profitable? Silence Therapeutics' return on equity of 0.00% beat 4basebio's return on equity.Company Net Margins Return on Equity Return on Assets Silence TherapeuticsN/A N/A N/A 4basebio N/A -231.29%-54.30% Summary4basebio beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks. Get 4basebio News Delivered to You Automatically Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart 4BB vs. The Competition Export to ExcelMetric4basebioBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£123.94M£127.82M£5.53B£2.97BDividend YieldN/A3.74%5.38%5.02%P/E Ratio-1,240.383.4127.40146.58Price / Sales398.514,115.67417.66240,166.96Price / Cash16.0813.1936.6327.97Price / Book-23.6043.398.085.31Net Income-£9.84M-£92.79M£3.16B£5.90B7 Day PerformanceN/A2.58%2.81%0.95%1 Month Performance-10.30%2.54%3.69%5.17%1 Year Performance-37.58%178.32%35.30%80.78% 4basebio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)4BB4basebio2.1319 of 5 starsGBX 967.50-1.8%GBX 1,600+65.4%-39.5%£123.94M£311K-1,240.38101SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health2.3507 of 5 starsGBX 124.40-1.9%GBX 455+265.8%-27.7%£373.67M£521.32K-5.10300Positive NewsOXBOxford Biomedica2.3515 of 5 starsGBX 311.50flatGBX 380+22.0%+4.9%£331.13M£98.31M-2.31891Positive NewsGap UpHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 191.10-2.0%N/A+129.7%£256.56MN/A-5.1134Gap UpVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,601-1.8%N/A-38.2%£136.20M£13.65M16.8212Gap DownAVCTAvacta GroupN/AGBX 30.88-0.4%N/A-45.5%£117.31M£26.29M-3.97120News Coverage Related Companies and Tools Related Companies Silence Therapeutics Competitors PureTech Health Competitors Oxford Biomedica Competitors Horizon Discovery Group plc (HZD.L) Competitors Faron Pharmaceuticals Oy Competitors Verona Pharma plc (VRP.L) Competitors Arix Bioscience Competitors Circassia Group Competitors Bioventix Competitors Avacta Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:4BB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
